Special aspects of cancer prevention trials
Open Access
Abstract
The results of early cancer prevention trials now are being reported, and new trials have begun or are being designed. Initial trials used agents such as vitamins and minerals, generally regarded as safe. The trials in progress are using similar agents or macronutrient manipulation, but some have incorporated drugs with low but definite toxic potential, such as tamoxifen. Appropriate prevention trial design requires careful consideration of agent toxicity and the use of such agents in healthy individuals. Full disclosure of risks and benefits to potential subjects is necessary. Other considerations are study duration (usually very long) and subject number (usually very large), both of which increase the cost of a trial. Successful prevention trials must overcome these barriers through innovative design. Possible innovations include the use of intermediate marker end-points, the enrollment of subjects at high risk for a specific cancer, and the use of volunteers to help conduct trials.Keywords
This publication has 8 references indexed in Scilit:
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male SmokersNew England Journal of Medicine, 1994
- Nutrition Intervention Trials in Linxian, China: Supplementation With Specific Vitamin/Mineral Combinations, Cancer Incidence, and Disease-Specific Mortality in the General PopulationJNCI: Journal of the National Cancer Institute, 1993
- Comparison of Low-Dose Isotretinoin with Beta Carotene to Prevent Oral CarcinogenesisNew England Journal of Medicine, 1993
- Chemoprevention for Breast Cancer: Are We Ready?JNCI: Journal of the National Cancer Institute, 1991
- Antiestrogen chemoprevention of breast cancer: Critical issues and researchPreventive Medicine, 1991
- Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 1990
- Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients With Node-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 1990
- 13-cis-Retinoic Acid in the Treatment of Oral LeukoplakiaNew England Journal of Medicine, 1986